Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
baricitinib + tofacitinib
- Development stage
- Unknown
- Lead developer
- Eli Lilly
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Baricitinib and tofacitinib are both oral Janus kinase (JAK) inhibitors approved for the treatment of rheumatoid arthritis. They work by inhibiting JAK enzymes involved in pro-inflammatory signaling pathways. Baricitinib (Olumiant) is a selective JAK1/2 inhibitor with moderate activity against TYK2 and limited activity against JAK3. Tofacitinib (Xeljanz) is a selective JAK1/3 inhibitor with limited inhibitory effect on JAK2 and TYK2. Both drugs have demonstrated rapid improvements in disease activity, function, and patient-reported outcomes in rheumatoid arthritis patients. They are typically used in patients who have had an inadequate response to one or more conventional synthetic DMARDs.
- Brand names
- Xeljanz + Olumiant
02
Targets
AAK1 (Adaptor-associated kinase 1)GAK (Cyclin G-associated kinase)JAK1 (Janus kinase 1)JAK2 (Janus kinase 2)JAK3 (Janus kinase 3)AMPK (Adenosine monophosphate–activated protein kinase)TNK1 (Tyrosine kinase non receptor 1)TYK2 (Tyrosine kinase 2)
Beyond the preview
Go deeper on baricitinib + tofacitinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on baricitinib + tofacitinib.